<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792712</url>
  </required_header>
  <id_info>
    <org_study_id>2014-09-003A</org_study_id>
    <nct_id>NCT02792712</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI</brief_title>
  <official_title>Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therefore, in this study, we try to evaluate the impact of clopidogrel loading dose 300mg vs.
      ticagrelor 180 mg on myocardial injury as measured by contrast-enhanced magnetic resonance
      imaging (CE-MRI) in STEMI patients undergoing primary PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All STEMI patients will be loaded with dual oral antiplatelet therapy of 300 mg aspirin
      combined with either 300 mg clopidogrel or 180 mg ticagrelor before PCI, followed by
      maintenance dose of 100 mg aspirin plus 75 mg clopidogrel QD or 90 mg ticagrelor BID. The
      duty interventional cardiologists will be responsible for patient randomization based on a
      pre-defined randomization chart. As it is a usual practice in Taiwan for door-to-balloon time
      to be within 90 minutes, we hence do not expect any impact on study results due to D2B time
      variation.

      All STEMI patients will receive loading dose of dual oral antiplatelet therapy with 300 mg
      aspirin combined with either 300 mg clopidogrel or 180 mg ticagrelor before PCI, followed by
      maintenance dose of 100 mg aspirin plus 75 mg clopidogrel QD or 90 mg ticagrelor BID.

      The primary variable is to compare myocardial salvage index (in %) as assessed by CE-MRI
      between 300-mg clopidogrel group and ticargrelor group. Enzymatic infarct size will also be
      assessed, and two methods will be used to decide that. The first is cardiac troponinI 72
      hours after pain onset , while the other is peak CK level after pain onset. Sampling timing
      of CK will be judged by the caring physicians.

      The secondary objectives include: myocardial infarct size (% of LV mass), the extent of MVO,
      the number of segments with &gt;75% of infarct transmurality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare myocardial infarct size (myocardial salvage index %) as assessed by CE-MRI between 300-mg clopidogrel group and 180-mg ticargrelor group</measure>
    <time_frame>4-10 days after the index event</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>STEMI_MRI_Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STEMI_MRI_Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180 mg LD，then 90 mg BID</description>
    <arm_group_label>STEMI_MRI_Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300 mg LD，then 75 mg QD</description>
    <arm_group_label>STEMI_MRI_Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures

          2. Adult patients aged 20 years or older

          3. STEMI within 12 hours of onset, defined as:presence of chest pain for &gt;30 minutes and
             &lt;12 hours after symptom onset; ST-segment elevation &gt;1 mm in ≥2 contiguous leads or
             presumably a new-onset left bundle-branch block on electrocardiogram.

          4. STEMI patients planned for PPCI

        Exclusion Criteria:

          1. STEMI &gt; 12 h of onset

          2. History of renal dysfunction requiring dialysis

          3. Evidence of malignant diseases

          4. Unwillingness to give out consent

          5. Contraindicated for ticagrelor or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao-Cheng Wu, MD, PhD.</last_name>
    <phone>(02)28712121</phone>
    <phone_ext>3793</phone_ext>
    <email>dcwu@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao-Cheng Wu, MD, PhD</last_name>
      <phone>+886-2-28712121</phone>
      <phone_ext>3655</phone_ext>
      <email>dcwu@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Tao-Cheng Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Tao-Cheng Wu, MD, PhD, Division of Cardiology, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Antiplatelet agents</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

